Dynavax commercializing Heplisav-B with $75M debt financing

To fund the commercialization of its Heplisav-B HBV vaccine, Dynavax announced March 18 it was drawing down a $75 million non-dilutive loan through an existing agreement with CRG Servicing LLC.

Dynavax Technologies Corp. (NASDAQ:DVAX) drew down the first $100 million tranche of the loan in February 2018...